Fig. 1

Remibrutinib inhibits HuMOG EAE. Dosing was started on day of immunization and continued to study end. a The 30 mg/kg dose showed statistically significant efficacy from day 11 onward (Kruskal–Wallis with Dunn’s test, n = 8–10 per group, means with standard errors). Peak BTK occupancy was assessed in b spleen, c lymph nodes and d brain homogenates 1, 5 and 8 h after the last dose. Shown are the BTK occupancy levels of individual animals and the group means with standard deviations as whiskers. Statistical significance of the 30 mg/kg dose group reached p < 0.05 from day 11 to study end (*) and p < 0.01 between days 13 and 23 (**) vs vehicle treatment (ANOVA followed by Dunnett’s test, mean ± , SEM, n = 5)